SUPN - Supernus Pharmaceuticals Inc
IEX Last Trade
35.13
0.130 0.370%
Share volume: 244,806
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$35.00
0.13
0.37%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-09 | 2023-03-09 | 2023-05-09 | 2023-08-08 | 2023-11-08 | 2024-02-27 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 1.695 B | 1.693 B | 1.703 B | 1.792 B | 1.293 B | 1.285 B | 1.278 B | 1.304 B | |
| Current Assets | 625.120 M | 663.886 M | 734.151 M | 883.340 M | 423.538 M | 449.360 M | 493.113 M | 544.321 M | |
| Inventories | 84.860 M | 83.165 M | 91.541 M | 91.147 M | 90.560 M | 83.480 M | 77.408 M | 75.079 M | |
| Other Current Assets | 21.410 M | 24.846 M | 15.779 M | 16.299 M | 44.766 M | 23.927 M | 16.676 M | 23.772 M | |
| Short Term Investments | 21.410 M | 24.846 M | 15.779 M | 16.299 M | 44.766 M | 23.927 M | 16.676 M | 23.772 M | |
| Total Receivables | 158.063 M | 164.086 M | 165.497 M | 143.568 M | 136.556 M | 141.764 M | 144.155 M | 147.734 M | |
| Current Cash | 360.787 M | 391.789 M | 461.334 M | 228.568 M | 151.656 M | 200.189 M | 254.874 M | 297.736 M | |
| Total Non-current Assets | 1.070 B | 1.029 B | 968.357 M | 908.468 M | 869.561 M | 835.800 M | 784.560 M | 759.769 M | |
| Property Plant Equipment | 16.317 M | 15.872 M | 15.173 M | 14.611 M | 14.186 M | 13.688 M | 13.530 M | 12.969 M | |
| Other Assets | 47.344 M | 41.290 M | 39.806 M | 40.184 M | 38.489 M | 38.821 M | 37.505 M | 38.367 M | |
| Intangible Assets | 743.405 M | 722.761 M | 702.463 M | 682.497 M | 662.389 M | 641.147 M | 599.889 M | 579.752 M | |
| Goodwill | 115.414 M | 117.383 M | 117.019 M | 117.019 M | 117.019 M | 117.019 M | 117.019 M | 117.019 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.695 B | 1.693 B | 1.703 B | 1.792 B | 1.293 B | 1.285 B | 1.278 B | 1.304 B | |
| Total liabilities | 853.539 M | 840.331 M | 816.304 M | 879.658 M | 373.191 M | 372.969 M | 356.157 M | 374.924 M | |
| Total current liabilities | 735.536 M | 725.987 M | 687.958 M | 731.545 M | 252.590 M | 287.534 M | 290.196 M | 314.554 M | |
| Accounts Payable | 35.518 M | 16.015 M | 10.543 M | 11.544 M | 4.400 M | 3.389 M | 1.964 M | 14.397 M | |
| Other liabilities | 21.610 M | 20.152 M | 42.539 M | 61.934 M | 42.124 M | 16.370 M | 7.802 M | 7.875 M | |
| Current long term debt | 400.909 M | 401.438 M | 401.968 M | 480.863 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 21.610 M | 20.152 M | 42.539 M | 61.934 M | 42.124 M | 16.370 M | 7.802 M | 7.875 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 841.434 M | 852.798 M | 886.204 M | 912.150 M | 919.908 M | 912.191 M | 921.516 M | 929.166 M | |
| Common stock | 53.426 M | 53.790 M | 54.114 M | 54.381 M | 54.503 M | 54.609 M | 54.652 M | 54.802 M | |
| Retained earnings | 454.015 M | 455.764 M | 481.245 M | 498.193 M | 497.362 M | 481.386 M | 482.561 M | 482.685 M |